Skip to main content
Fresenius SE & Co. KGaA logo

Fresenius SE & Co. KGaA - Investor Relations & Filings

Listed IPO Jan 2011
Ticker · FRE ISIN · DE0005785604 LEI · XDFJ0CYCOO1FXRFTQS51 F Human health and social work activities
Open in API
Filings indexed 1,405 across all filing types
Latest filing 2026-07-23 Capital/Financing Update
Country DE Germany
Listing F FRE · 12 venues

Key figures FY2025

Period ended 2025-12-31 · EUR
Headline annual figures for Fresenius SE & Co. KGaA, fiscal year 2025, reported in EUR, with the source filing for each figure.
Total Revenues EUR 22.87B per the Annual Report filed 2026-04-16
Net Income EUR 1.33B per the Annual Report filed 2026-04-16
Total Assets EUR 41.40B per the Annual Report filed 2026-04-16
Total Equity EUR 19.77B per the Annual Report filed 2026-04-16
Cash from Ops EUR 2.57B per the Annual Report filed 2026-04-16

As reported by the issuer in the filings linked above. Figures are normalized for comparability; consult the source filing for the authoritative statement.

About Fresenius SE & Co. KGaA

https://www.fresenius.com/

Fresenius SE & Co. KGaA is a global healthcare company that provides system-critical products and services for leading therapies for the care of critically and chronically ill patients. The company's portfolio encompasses a wide range of products and services for dialysis, hospitals, and outpatient medical care. Key offerings include intravenously administered generic drugs, biopharmaceuticals, biosimilars, clinical nutrition, and infusion therapies. Additionally, the company operates a large network of private hospitals and outpatient centers. Through its strategic investment in Fresenius Medical Care, it is a leading global provider of products and services for individuals with renal diseases.

Recent filings

Filing Released Lang Actions
Fresenius establishes venture fund of more than 200 million to drive healthcare innovation
Capital/Financing Update Classification · 95% confidence The document announces that Fresenius is establishing a corporate venture capital fund of more than 200 million euros to drive healthcare innovation (Fresenius Ventures). This falls squarely under capital allocation and financing/strategic corporate decisions regarding funding units, fitting the Capital/Financing Update (CAP) category.
2026-07-23 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 100% confidence The document is a formal notification of a change in major shareholding (FMR LLC's interest in Fresenius SE & Co. KGaA) as required by the German Securities Trading Act (WpHG). This falls under the category of 'Major Shareholding Notification'.
2026-06-04 English
Fresenius SE & Co. KGaA: Michael Sen, buy
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a person discharging managerial responsibilities (Michael Sen, a member of the managing body). It details the acquisition of shares, including price, volume, date, and venue. This aligns perfectly with the definition of a Director's Dealing (DIRS) filing.
2026-06-01 English
2026 Annual General Meeting of Fresenius: Shareholders approve all agenda items
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is a corporate news release reporting the voting outcomes of the 2026 Annual General Meeting, including approval percentages for various agenda items and dividend decisions. It does not present the AGM materials themselves, proxy statements, or the full annual report, but specifically declares vote results, fitting the definition of a Declaration of Voting Results & Voting Rights Announcement.
2026-05-23 English
2026 Annual General Meeting: Fresenius delivers strong performance in 2025 and proposes 5% increase in dividends
AGM Information Classification · 85% confidence The document is a corporate press release summarizing the 2026 Annual General Meeting of Fresenius SE & Co. KGaA, highlighting performance, proposed dividend and linking to the AGM speeches. It is not the full annual report or an earnings release, nor does it report vote results. This aligns with “AGM Information” covering materials and presentations shared at the AGM.
2026-05-22 English
Major Shareholding Notification 2026
Major Shareholding Notification Classification · 95% confidence The document is a formal notification under Article 40 Section 1 of Germany’s Securities Trading Act (WpHG) detailing the acquisition/disposal of shares and voting rights by The Capital Group Companies, Inc. It specifies the date a threshold was crossed, percentages before and after, and chain of controlled undertakings. There is no reference to AGM vote results; rather, it reports a change in significant shareholding. This matches the ‘Major Shareholding Notification’ category (MRQ).
2026-05-15 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.